The Complete GLP-1 Peptide Guide
A research-backed deep dive into GLP-1 receptor agonists — how they work, what the clinical trials actually show, and everything you need to know before talking to a provider.
What Are GLP-1 Receptor Agonists?
GLP-1 receptor agonists (GLP-1 RAs) are a class of peptide-based medications that mimic the action of glucagon-like peptide-1, a naturally occurring gut hormone. They were originally developed to treat type 2 diabetes and have since become the most-studied pharmacological intervention for obesity in decades.[1]
Glucagon-like peptide-1 is secreted by L-cells in the small intestine and colon in response to food intake. Under normal physiology, GLP-1 has a short half-life of just 1–2 minutes before being degraded by the enzyme dipeptidyl peptidase-4 (DPP-4). The pharmaceutical versions used clinically are engineered to resist this degradation, extending their half-life to hours or days.[2]
A Brief History
The first GLP-1 RA approved for clinical use was exenatide (Byetta), in 2005, derived from the salivary secretion of the Gila monster lizard — which was found to contain a GLP-1-like peptide called exendin-4. Liraglutide followed in 2010. The more potent once-weekly semaglutide arrived in 2017 for diabetes (Ozempic) and in 2021 for obesity (Wegovy). Tirzepatide — a dual GIP/GLP-1 agonist — received FDA approval in 2022 and 2023.[3]
GLP-1 RAs are peptide-based therapeutics — they are synthetic analogs of naturally occurring hormones. They are distinct from other weight-loss approaches in that they act on hormonal signaling pathways governing appetite, blood sugar regulation, and gastric emptying, rather than simply blocking fat absorption or stimulating metabolism via sympathomimetic pathways.
Why They're in the Headlines Right Now
Global demand for semaglutide (Wegovy, Ozempic) created severe supply shortages from 2022 to 2024, which in turn expanded the compounding pharmacy market for "compounded semaglutide" — a grey-market alternative that the FDA repeatedly warned against. As Novo Nordisk's manufacturing caught up, the FDA declared the shortage resolved in February 2025 and issued warning letters to compounding pharmacies. The legal and access landscape continues to shift rapidly.[4]
How GLP-1 Peptides Work
Understanding the mechanism helps separate what these drugs are actually doing from the marketing narrative around them. GLP-1 RAs bind to and activate GLP-1 receptors (GLP-1R), which are expressed throughout the body — including the pancreas, brain, gut, heart, and kidneys.[2]
Pancreatic Effects
The original clinical rationale for GLP-1 RAs was glycemic control. In the pancreas, GLP-1R activation stimulates glucose-dependent insulin secretion from beta cells — meaning insulin is released in response to glucose, but not in isolation (reducing hypoglycemia risk compared to sulfonylureas). GLP-1 RAs also suppress glucagon secretion from alpha cells, which further reduces hepatic glucose output.[5]
Central Nervous System Effects (Why They Reduce Appetite)
This is where GLP-1 RAs diverge from their original diabetes framing. GLP-1 receptors are expressed in the hypothalamus, brainstem, and dopaminergic reward circuits. Activation of these receptors — particularly in the arcuate nucleus and nucleus tractus solitarius — reduces hunger signals and increases satiety signaling.[6]
In other words: these drugs change how your brain processes the drive to eat. They do not simply make food taste worse or suppress hunger mechanically — they appear to alter the reward valence of food, reducing cravings and the hedonic drive to eat. This is why patients frequently report not thinking about food the way they did before.
Gastric Emptying
GLP-1 RAs slow gastric emptying — the rate at which food moves from the stomach into the small intestine. This contributes to satiety (you feel full longer) and also attenuates post-meal glucose spikes. The tradeoff is that this mechanism underlies many of the GI side effects (nausea, vomiting, constipation) observed in clinical use.[5]
Cardiovascular Effects
GLP-1 receptors in the heart and blood vessels mediate effects beyond glycemic control. Multiple large cardiovascular outcome trials have demonstrated that semaglutide and liraglutide reduce major adverse cardiovascular events (MACE) in high-risk patients — a finding that has expanded their clinical use well beyond diabetes management.[7]
GLP-1 RAs work through at least four parallel pathways: (1) glucose-dependent insulin stimulation in the pancreas, (2) appetite suppression via central nervous system GLP-1R signaling, (3) slowed gastric emptying for prolonged satiety, and (4) direct cardiovascular effects. The weight loss observed is primarily mediated by the CNS appetite reduction pathway — not by metabolic rate changes or fat malabsorption.
Unlock the Complete GLP-1 Guide
You've seen the foundation. The full guide covers what actually matters when you're making decisions — the clinical data, the risks, and what to ask your provider.
One-time purchase · Instant access · PDF included · 30-day guarantee
Key Peptides: A Comparison Deep-Dive
Three agents dominate the current landscape: semaglutide, tirzepatide, and liraglutide. A fourth, exenatide, is older and less used. Here's how they compare across the dimensions that matter.
Table 1: Pharmacological Comparison
| Drug | Target | Dosing Frequency | Half-Life | FDA Approvals | Branded Names |
|---|---|---|---|---|---|
| Semaglutide | GLP-1R | Once weekly (injection) Once daily (oral) |
~1 week | T2D, Obesity, CV risk reduction | Ozempic, Wegovy, Rybelsus |
| Tirzepatide | GLP-1R + GIPR (dual) | Once weekly | ~5 days | T2D, Obesity | Mounjaro, Zepbound |
| Liraglutide | GLP-1R | Once daily | ~13 hours | T2D, Obesity (3mg), CV risk | Victoza, Saxenda |
| Exenatide | GLP-1R | Twice daily or once weekly | 2.4 hrs (IR) ~2 weeks (ER) |
T2D only | Byetta, Bydureon |
Table 2: Weight Loss Efficacy (Clinical Trial Data)
| Drug | Trial | Population | Mean Weight Loss | % Achieving ≥15% Loss | Duration |
|---|---|---|---|---|---|
| Semaglutide 2.4mg | STEP 1 | Adults with obesity (no T2D) | −14.9% | 32% | 68 weeks |
| Tirzepatide 15mg | SURMOUNT-1 | Adults with obesity (no T2D) | −20.9% | 55% | 72 weeks |
| Liraglutide 3.0mg | SCALE Obesity | Adults with obesity (no T2D) | −8.0% | 11% | 56 weeks |
| Semaglutide 2.4mg | SELECT | Overweight/obese adults, CVD, no T2D | −9.4% | — | ~3.3 years |
Tirzepatide's efficacy numbers are genuinely higher than semaglutide's, though direct head-to-head trials (SURMOUNT-5) show a ~5.5% additional weight loss advantage for tirzepatide. Both far outperform liraglutide for weight loss. However, liraglutide has a longer safety track record and is available generically in some markets, which affects cost and access calculations.
Table 3: Access, Cost & Practical Considerations
| Drug | List Price (US) | Generic Available? | Insurance Coverage | Compounding Status (2026) |
|---|---|---|---|---|
| Semaglutide (Wegovy) | ~$1,350/mo | No | Highly variable; improving | Compounding banned |
| Tirzepatide (Zepbound) | ~$1,060/mo | No | Highly variable | In legal dispute |
| Liraglutide (Saxenda) | ~$1,400/mo | No (US) | Variable | Not in shortage |
| Semaglutide (Ozempic) | ~$935/mo | No | Better (T2D indication) | Compounding banned |
Get notified when new guides drop.
Recovery peptides, longevity protocols, and regulatory updates — when they publish, you'll know.
Clinical Evidence Review
This section summarizes the key trial evidence beyond efficacy numbers. Understanding trial design helps evaluate the strength of claims you'll encounter from providers, clinics, and vendors.
The STEP Trials (Semaglutide)
The STEP (Semaglutide Treatment Effect in People with Obesity) program comprised eight trials investigating semaglutide 2.4mg weekly for weight management. Key findings:[8]
- STEP 1 (68 weeks, n=1,961): −14.9% weight loss vs. −2.4% for placebo in adults with obesity/overweight without T2D.
- STEP 2 (68 weeks, n=1,210): −9.6% in patients with T2D, consistent with the glycemic benefit baseline reducing magnitude.
- STEP 4 (withdrawal design): 68% of weight lost was regained by 1 year after discontinuation. This is the most important finding most patients are not told about.
- STEP 5 (2-year trial): Weight loss maintained at −15.2% at 104 weeks, suggesting sustained efficacy with continued use.
The SURMOUNT Trials (Tirzepatide)
SURMOUNT-1 is the landmark obesity trial for tirzepatide, running 72 weeks in 2,539 adults with obesity but without T2D.[9] The 15mg dose produced mean weight loss of −20.9%, with 91% of participants achieving ≥5% weight loss and 55% achieving ≥15%. These numbers are materially better than semaglutide in the same population, though the trials were not designed as head-to-head comparisons.
SURMOUNT-5 (direct head-to-head): Published in late 2024, this was the first randomized trial directly comparing tirzepatide vs. semaglutide in a non-T2D population. Over 72 weeks, tirzepatide 15mg produced ~5.5 percentage points more weight loss. This confirms tirzepatide's efficacy advantage — though the clinical significance varies by patient.
Cardiovascular Outcomes
The SELECT trial was a pivotal landmark: 17,604 adults with overweight/obesity and established cardiovascular disease (but without T2D) randomized to semaglutide 2.4mg vs. placebo for ~3.3 years.[10] Semaglutide reduced MACE (cardiovascular death, non-fatal MI, non-fatal stroke) by 20%. This was the first major weight-loss trial to demonstrate a cardiovascular mortality benefit independent of glycemic effects, and it substantially expanded semaglutide's clinical use case.
What the Trials Don't Tell You
- Long-term use beyond 2–3 years is not well characterized. Most pivotal trials run 68–72 weeks. We don't yet know what a decade of continuous GLP-1 RA use looks like.
- Non-responders exist. Roughly 5–10% of trial participants do not achieve clinically meaningful weight loss on these medications. The predictors of non-response are not well understood.
- Lean mass loss is real. Multiple analyses have shown that 25–40% of weight lost on GLP-1 RAs is lean mass (muscle), not just fat. Resistance exercise and adequate protein intake appear to mitigate but not eliminate this.
- Most trials excluded complex comorbidities. Real-world populations are older, have more conditions, and take more medications than trial participants.
The lean mass loss finding deserves more attention than it gets in popular media. Studies using DEXA and MRI suggest that as much as 30–40% of total weight lost on semaglutide is fat-free mass. For older adults, this raises genuine concerns about sarcopenia risk with long-term or repeated use. This is not a reason to avoid these medications, but it is a reason to take resistance training and protein intake seriously if you use them.
Risks, Side Effects & Contraindications
GLP-1 RAs have a well-characterized safety profile across thousands of patient-years of data. The major side effects are primarily gastrointestinal; rare but serious adverse events exist and require careful patient selection.[11]
Common Side Effects (GI Predominant)
- Nausea — most common, reported in 30–50% of patients, particularly during dose escalation. Usually transient, peaking in weeks 1–8.
- Vomiting — 15–25%; typically accompanies nausea and resolves with dose stabilization.
- Diarrhea — 20–30%; related to altered GI motility.
- Constipation — 15–25%; counterintuitive given above, but related to slowed gastric emptying.
- GERD / heartburn — increased reflux symptoms due to delayed gastric emptying; clinically significant in a subset.
The most reliable strategy is slow dose titration — starting at the lowest dose and increasing every 4–8 weeks based on tolerance. Eating smaller meals, avoiding high-fat foods, and not lying down immediately after meals also help. GI symptoms that persist beyond the dose titration period or cause significant dehydration require medical evaluation.
Serious and Rare Adverse Events
- Pancreatitis — an elevated risk signal exists in pharmacovigilance data, though causality has not been definitively established in RCTs. Patients with a history of pancreatitis are typically excluded from use.
- Gallbladder disease — cholelithiasis (gallstones) and cholecystitis occur at higher rates with GLP-1 RA use, likely related to rapid weight loss and altered gallbladder motility. The SCALE trial found a ~3x increased incidence vs. placebo.
- Gastroparesis (delayed gastric emptying) — distinct from normal GI side effects; some patients develop clinically significant gastroparesis requiring discontinuation. Important for anesthesiologists to know before procedures.
- Thyroid C-cell tumors (rodent data) — GLP-1 RAs cause dose-dependent C-cell hyperplasia and tumors in rodents. Medullary thyroid carcinoma has not been established in humans, but the FDA maintains a black box warning. Patients with personal or family history of MTC or MEN2 should not use these drugs.
All GLP-1 RAs carry an FDA black box warning for risk of thyroid C-cell tumors based on rodent carcinogenicity data. While no causal link has been established in humans, patients with personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 (MEN2) should not use GLP-1 receptor agonists.
Drug Interactions
- Oral medications — slowed gastric emptying can delay absorption of co-administered oral drugs. Particular attention required with oral contraceptives, thyroid medications, and drugs with narrow therapeutic windows.
- Insulin and sulfonylureas — combination increases hypoglycemia risk; dose adjustments typically required.
- Warfarin — altered absorption may affect INR; increased monitoring recommended.
Who Should Not Use GLP-1 RAs
- Personal or family history of medullary thyroid carcinoma or MEN2
- History of severe pancreatitis
- Pregnancy or breastfeeding (no adequate safety data)
- Severe gastroparesis
- Known hypersensitivity to the drug or any excipients
Regulatory Status (2025–2026)
The regulatory landscape for GLP-1 peptides is the most rapidly evolving aspect of this space. Here's the current status and what's changing.
FDA-Approved Agents
As of May 2026, the following are FDA-approved for obesity or weight management:
- Semaglutide 2.4mg (Wegovy) — chronic weight management in adults with BMI ≥30 or ≥27 with weight-related comorbidity. Added cardiovascular risk reduction indication in 2024 following SELECT trial data.
- Tirzepatide (Zepbound) — chronic weight management in adults with BMI ≥30 or ≥27 with weight-related comorbidity, approved June 2023.
- Liraglutide 3.0mg (Saxenda) — chronic weight management, approved 2014; also indicated for adolescents 12+ since 2020.
Compounding Pharmacy Status
This is where the landscape shifted dramatically in 2025. During the period of semaglutide shortage (2022–2025), hundreds of compounding pharmacies produced and sold compounded semaglutide — often at significantly lower prices than the brand-name products.
In February 2025, the FDA declared that the semaglutide shortage was resolved. Under FDCA Section 503A and 503B, compounding pharmacies are prohibited from producing drugs that are not on the FDA drug shortage list, unless they meet specific clinical need criteria. The FDA issued warning letters to major compounders in March–April 2025, and enforcement actions accelerated.[4]
Semaglutide: Compounding of commercially available semaglutide formulations is now prohibited for most compounders. 503B outsourcing facilities may still produce patient-specific formulations under limited conditions. Tirzepatide: Still under active FDA review and litigation; some compounders continue to argue access rights. The legal situation as of May 2026 remains unsettled. If you are obtaining GLP-1 peptides from compounding pharmacies, verify the pharmacy's 503B status and obtain a COA (certificate of analysis) for every lot.
International Access
Access varies significantly by country. In several European markets, semaglutide for obesity (Wegovy) has been approved but reimbursement is limited. In the UK, the NHS began prescribing Wegovy through specialist weight management services in 2024, with eligibility criteria. Tirzepatide has received EMA approval as Mounjaro (T2D) and Zepbound (obesity), with availability expanding across EU member states. In many markets, patients with diabetes have significantly better access and reimbursement than those using the drugs for obesity alone.
Questions to Ask Your Provider
If you're considering GLP-1 therapy, the following questions will help you have a more informed conversation with your prescriber. The goal isn't to interrogate your doctor — it's to ensure you understand the decision you're making.
Before Starting
- Am I a good candidate based on my medical history? (Specifically: any thyroid conditions, history of pancreatitis, current medications)
- Which agent are you recommending and why that one specifically for me?
- What's the titration schedule, and what side effects should prompt me to call you vs. wait it out?
- What do we expect to achieve in 12 weeks? 6 months? What's the threshold at which we'd reconsider?
- What lifestyle changes do you recommend alongside the medication, particularly around protein intake and resistance exercise?
About Long-Term Use
- What happens when I stop? What's your plan for managing the weight regain risk?
- How long are you willing to prescribe this medication, and what would change that?
- How will you monitor for side effects over time — specifically bone density, muscle mass, and gallbladder health?
About Access and Cost
- Does my insurance cover this, and what documentation do you need to submit?
- If insurance doesn't cover it, what's the manufacturer's patient assistance program eligibility?
- What's your position on compounding pharmacies? Do you prescribe through them?
Be cautious of any provider who: does not discuss lean mass considerations, doesn't ask about thyroid or pancreatic history, recommends compounded semaglutide without explaining the regulatory situation, or dismisses questions about long-term use with "studies show it's safe." The evidence base is strong but not unlimited — good clinicians know where the data ends.
Tracking Your Own Progress
If you're on GLP-1 therapy, consider tracking beyond scale weight. Body composition (via DEXA or bioelectrical impedance) gives you insight into whether you're losing fat vs. muscle. Grip strength is a useful proxy for functional lean mass and easy to measure at home with a dynamometer. Maintaining or improving strength metrics alongside weight loss is the goal, not just hitting a number on the scale.
Sources & Citations
- 1Nauck MA, Quast DR, Wefers J, Meier JJ. GLP-1 receptor agonists in the treatment of type 2 diabetes – state-of-the-art. Mol Metab. 2021;46:101102.
- 2Drucker DJ. Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1. Cell Metab. 2018;27(4):740-756.
- 3U.S. Food & Drug Administration. Drugs@FDA: FDA-Approved Drugs. Tirzepatide (Mounjaro) approval history. 2022.
- 4U.S. Food & Drug Administration. Drug Shortage Database — Semaglutide Injection. Removal from shortage list, February 2025.
- 5Holst JJ, Rosenkilde MM. GIP as a Therapeutic Target in Diabetes and Obesity: Insight From Incretin Co-agonists. J Clin Endocrinol Metab. 2020;105(8):e2710-e2719.
- 6Katsurada K, Yada T. Neural effects of gut- and brain-derived glucagon-like peptide-1 and its receptor agonist. J Diabetes Investig. 2016;7(Suppl 1):64-69.
- 7Marso SP, et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes (SUSTAIN-6). N Engl J Med. 2016;375:1834-1844.
- 8Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). N Engl J Med. 2021;384:989-1002.
- 9Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). N Engl J Med. 2022;387:205-216.
- 10Lincoff AM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT). N Engl J Med. 2023;389:2221-2232.
- 11Smits MM, Van Raalte DH. Safety of Semaglutide. Front Endocrinol. 2021;12:645563.
- 12Wilding JPH, et al. Weight Regain and Cardiometabolic Effects after Withdrawal of Semaglutide (STEP 4 Withdrawal Extension). Diabetes Obes Metab. 2022;24(8):1553-1564.